|
|
Vaccine Detail
|
Recombinant Adenovirus-Interferon/Syn3 Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Adenovirus-Interferon/Syn3 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007001
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- IFNA2
gene engineering:
- Preparation: A recombinant adenovirus gene delivery system (rAd-IFN) in conjunction with the novel small molecule excipient Syn3 is used for gene delivery and expression of IFN (Nagabhushan et al., 2007).
- Description: This is for Bladder Cancer (NCT02773849).A non-replicating recombinant adenovirus type 5 (Ad5)-vector encoding the gene for interferon alpha-2b (IFN alpha-2b) and the gene transfer enhancement agent Syn 3, with potential antineoplastic activity. Upon intravesical administration, recombinant adenovirus-interferon with Syn3 transfects both cancerous and normal bladder cells, and the adenovirus secretes interferon (IFN alpha-2b) into the bladder. IFN exerts a direct antitumor killing effect and a bystander effect, thereby killing adjacent, non-transfected cancerous bladder cells. Syn 3 enhances the ability of the adenoviral vector to transfect cells (Shore et al., 2017; NCIT_C104743).
|
| Host Response |
|
|
| References |
Nagabhushan et al., 2007: Nagabhushan TL, Maneval DC, Benedict WF, Wen SF, Ihnat PM, Engler H, Connor RJ. Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. Cytokine & growth factor reviews. 2007; 18(5-6); 389-394. [PubMed: 17692556].
NCIT_C104743: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104743]
NCT02773849: [https://clinicaltrials.gov/ct2/show/NCT02773849?term=Instiladrin&rank=1]
Shore et al., 2017: Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017; 35(30); 3410-3416. [PubMed: 28834453].
|
|
